Overview

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

Status:
Recruiting

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the clinical efficacy of 5% lifitegrast ophthalmic solution in subjects with dry eye disease secondary to ocular Graft-versus-Host Disease compared to standard of care artificial tears.

Phase:

Early Phase 1

Details

Lead Sponsor:

Richard W Yee, MD

Collaborator:

Novartis

Treatments:

Lifitegrast
Ophthalmic Solutions